PRIMARY STUDY
Case report: Medical cannabis-warfarin drug-drug interaction
Key Findings: Contrary to the currently available literature that suggests that cannabinoids can increase warfarin’s effect no such data was observed in the case of an 85-year-old patient who despite starting an oromucosal cannabis regimen (0.3 mg of THC and 5.3 mg CBD once daily and an additional 0.625 mg of THC and 0.625 mg CBD once daily as needed) had minimal International Normalized Ratio (INR) fluctuations from October 2018 to September 2019. The authors hypothesize that the potential for warfarin and THC/CBD interactions may be dose- or route-dependent.
Type of Study: Meta-analysis
Study Sample Size: 1
Study Result: Inconclusive
Research Location(s): United States
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype II, Chemotype III
Sub-Ratio: 1:18 (THC:CBD) 1:1 (THC:CBD)
Route of Administration: Oral (Ingestion)
Citation: Thomas TF, et al. Case report: Medical cannabis-warfarin drug-drug interaction. J Cannabis Res. 2022; 4:6. doi: 10.1186/s42238-021-00112-x
Authors: Thomas TF, Metaxas ES, Nguyen T, Bennett W, Skiendzielewski KV, Quinn DH, Scaletta AL
